Skip Navigation

Annals of Oncology 2007 18(5):811; doi:10.1093/annonc/mdm131
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Predicting early relapse in postmenopausal women with hormone receptor-positive breast cancer
 
A total of five trials have shown that aromatase inhibitors improve disease-free survival compared with tamoxifen alone. ATAC (anastrozole) and BIG 1-98 (letrozole) compared up-front aromatase inhibitors for 5 years to tamoxifen for 5 years. While awaiting results from ongoing randomized trials, Mauriac et al. have examined prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices. . . . [Full Text of this Article]


   Optimal chemotherapy for good-risk metastatic nonseminomatous germ-cell tumors
 

   Prognostic factors for diffuse large B-cell lymphoma
 

   Monitoring of renal function in cancer patients
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L Mauriac, A Keshaviah, M Debled, H Mouridsen, JF Forbes, B Thürlimann, R Paridaens, A Monnier, I Láng, A Wardley, J-M Nogaret, RD Gelber, M Castiglione-Gertsch, KN Price, AS Coates, I Smith, G Viale, M Rabaglio, N Zabaznyi, A Goldhirsch, and On the behalf of BIG 1-98 Collaborative Group and International Breast Cancer Study Group, Berne, Switzerland
Ann Oncol 2007 18: 859-867. [Abstract] [FREE Full Text]  

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
S Culine, P Kerbrat, A Kramar, C Théodore, C Chevreau, L Geoffrois, NB Bui, J Pény, A Caty, R Delva, P Biron, K Fizazi, J Bouzy, and JP Droz
Ann Oncol 2007 18: 917-924. [Abstract] [FREE Full Text]  

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
H Veelken, S Vik Dannheim, J Schulte Moenting, UM Martens, J Finke, and A Schmitt-Graeff
Ann Oncol 2007 18: 931-939. [Abstract] [FREE Full Text]  

Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice
M Kleber, M Cybulla, K Bauchmüller, G Ihorst, B Koch, and M Engelhardt
Ann Oncol 2007 18: 950-958. [Abstract] [FREE Full Text]